Business Wire

VA-HILTON

15.12.2020 18:02:13 CET | Business Wire | Press release

Share
In a Year Like No Other, Hilton Grows to Milestone 1 Million Rooms and Responds to Pandemic with Innovations for Guests, Positive Impact for Communities

In a year when the travel industry faced challenges like never before, Hilton (NYSE: HLT) weathered the storm by staying true to its founding purpose – to fill the earth with the light and warmth of hospitality. As the COVID-19 pandemic created unprecedented challenges for the travel and tourism industry, Hilton developed industry-leading guest innovations, reached significant growth milestones and continued to positively impact communities around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005839/en/

Even as the company faced the biggest test in its 101-year history, Hilton’s resilient, capital-light business model enabled it to organically reach its 1 million room milestone in the fourth quarter.

Three of the hotels that helped the company cross this important threshold paint a picture of Hilton’s global growth story: Hilton Garden Inn Umhlanga Arch in South Africa, illustrating the company’s expansion into Africa; Tru by Hilton Savannah Airport , showcasing the power of the fastest-growing new brand in Hilton’s portfolio; and the Hilton Garden Inn Guizhou Maotai Town in China, helping deliver on the company’s ambitious growth goals in the APAC market.

Meanwhile, Hilton’s overall development pipeline remains strong, with 2,640 hotels and more than 408,000 rooms globally*.

“It’s been a year unlike any other, but even in the face of incredible challenges, our Team Members and owners have proven that travel is an unstoppable force for good,” said Chris Nassetta, president & CEO, Hilton. “Thanks to their grit and determination, Hilton has made a difference in the lives of so many and positively impacted communities at a time when our hospitality is needed more than ever – and together we look forward to creating even more meaningful memories in the year ahead.”

Throughout 2020, Hilton, in partnership with its hotel ownership community, has found innovative and meaningful ways to adapt to the changing needs of its guests, Team Members and communities:

Guest Experience

The pandemic rapidly changed guest behavior, priorities and concerns. Hilton responded with start-up style speed, grounded in more than a century of hospitality know-how to provide reassurance to travelers.

Among the innovations:

  • Launched Hilton CleanStay TM , an industry-defining standard of cleanliness and disinfection in collaboration with RB, maker of Lysol and Dettol and in consultation with Mayo Clinic
  • Redesigned meeting and event experiences and set new standards for event cleanliness and customer service with the launch of Hilton EventReady with CleanStay TM
  • Modified cancellation policies and took a number of steps to provide even more flexibility for Hilton Honors members including status and Points extensions
  • Created opportunities for Hilton Honors members to respond to the global pandemic by donating their Points to convert into cash and send directly to organizations including World Central Kitchen , Clean the World , Project Hope or Direct Relief
  • Provided alternative remote working options through the launch of WorkSpaces by Hilton in the U.S., Canada and the United Kingdom
  • Continued to provide contactless guest experience options through the free Hilton Honors app , enabling guests to personalize their experience with the ability to choose their rooms, check-in and out digitally and use their phones as digital keys. Guests have now used Hilton’s Digital Key to open more than 100 million doors worldwide
  • Inspired travelers to make new memories with the global launch of our insights-driven marketing campaign, “To New Memories
  • Revealed, for the first time ever, DoubleTree by Hilton’s official chocolate chip cookie recipe so guests could create an at-home version of this iconic travel treat

Response to Communities

Hilton continued to find inventive ways to address some of the most critical, immediate needs of the communities where it operates.

  • Partnered with American Express to donate up to 1 million hotel room nights across the U.S. for frontline medical professionals leading the fight against COVID-19
  • Expanded partnership with American Express through a $1 million contribution from American Express to World Central Kitchen , to provide healthy, freshly prepared meals to the frontline healthcare professionals who stayed at Hilton properties in cities across the U.S. during the coronavirus pandemic
  • Revealed 2020 Hilton Effect Foundation Grants and reached more than $1 million in global COVID-19 community response efforts
  • Extended Hilton’s hospitality to help the travel industry come together to overcome the global pandemic including sharing countless stories of teams around the world supporting each other and helping their communities
  • Supported Hilton Team Members searching for virtual and remote volunteer opportunities, including during its annual Hilton Effect Week volunteer event and through innovative partnerships with groups including Clean the World, Meals on Wheels and more
  • Remained committed to the company’s Travel with Purpose 2030 Goals to cut the company’s environmental footprint in half and double its social impact investments worldwide. These efforts led to Hilton being named the global industry leader in sustainability for the second consecutive year on the Dow Jones Sustainability Indices

Continued Global Growth and Expansion

Hilton kept dreams of traveling alive by opening exciting new properties around the world. All the while, the company advocated on behalf of owners, many of whom are small businesses, who struggled with the travel decline.

Response to Team Members

2020 saw Hilton go from being named the #1 Best Company to Work for in the U.S. to, weeks later, having to furlough thousands of Team Members due to the impact of COVID-19 on travel and tourism. At every turn, the company leaned into its values to navigate these tough decisions.

  • Activated Hilton’s Team Member Assistance Fund to support Hilton Team Members who have been directly impacted by COVID-19 or have a family member impacted by the virus
  • Reversed its recruitment engine to connect Team Members impacted by furloughs and layoffs with access to more than a million job opportunities through the Hilton Workforce Resource Center
  • Launched a new Hilton Alumni Network portal with access to relevant career opportunities, resources, news and information
  • Committed to an expedited recruitment process for Team Members who reapply for future roles when conditions allow
  • Extended Team Member Hilton Honors status and access to Go Hilton, Hilton’s industry-leading Team Member travel program, for departing Team Members, and offered improved Honors status to current Team Members
  • Continued to earn recognition as a top workplace, even as the pandemic continued, including being named to the top spot on the 2020 list of Best Workplaces in Greater China
  • Recognized the heroic actions of frontline Team Members with the creation of a new Hospitality Heroes Award
  • Listened to Team Members and relaunched the network of eight Team Member Resource Groups committed to building communities across the organization, and introduced a Courageous Conversation series to foster meaningful dialogue to bring about lasting change in the midst of an evolving social justice landscape

To learn more about Hilton, please visit: newsroom.hilton.com .

* Unless otherwise indicated, all hotel data reflects Hilton’s third quarter 2020 announcement (November 4). More information can be found on Hilton’s Investor Relations website.

About Hilton

Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 18 world-class brands comprising more than 6,300 properties and more than one million rooms, in 118 countries and territories. Dedicated to fulfilling its mission to be the world’s most hospitable company, Hilton has welcomed more than 3 billion guests in its more than 100-year history, earned a top spot on the 2020 World’s Best Workplaces list, and was named the 2020 Global Industry Leader on the Dow Jones Sustainability Indices. In 2020, Hilton CleanStay was introduced, bringing an industry-defining standard of cleanliness and disinfection to hotels worldwide. Through the award-winning guest loyalty program Hilton Honors, the more than 110 million members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy, plus enjoy instant benefits, including contactless check-in with room selection, Digital Key, and Connected Room. Visit newsroom.hilton.com for more information, and connect with Hilton on Facebook , Twitter , LinkedIn , Instagram and YouTube .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye